DEPLOYDatabase

Deployment

EksoNR at United States

Powered (motor-driven) lower-limb exoskeleton for clinical gait rehabilitation (stroke, spinal-cord injury, acquired brain injury). User intent plus weight-shift triggers powered steps; the device powers the joints, the clinician/patient sets the session. FDA cleared.

EksoNR by Ekso Bionics · Operated by Ekso Bionics · Catalog entry · 2 sources · not yet field-verified · Exoskeletons

Track EksoNR at United States

Recent coverage

See all coverage →

Machine-readable surfaces

Footage

PRIMARY SOURCE
Courtesy of Ekso Bionics

Ekso Bionics footage of a stroke patient performing clinician-supervised assisted stepping in the EksoNR rehabilitation exoskeleton. The device provides adaptive assistance and the patient initiates each step (the robot does not walk the patient), so it is not autonomous.

EksoNR is FDA-cleared for stroke, SCI, acquired brain injury, and multiple sclerosis (first exoskeleton cleared for MS, June 2022). Deployed in 375+ rehabilitation centers worldwide with 200+ published articles. Q1 2026 revenue: Americas $1.55M, EMEA $0.55M, APAC $0.04M. Company disclosed going-concern warning in Q1 2026 10-Q. Pending Business Combination with Applied Digital Cloud (ChronoScale). Go-to-market partners include National Seating & Mobility, Bionic Prosthetics & Orthotics Group, and Ottobock Patient Care.

Key facts

FDA clearances
Stroke (2016), SCI T4-L5 and C7-T3 ASIA D, ABI (2020), MS (June 2022, K220988) — first exoskeleton cleared for MS rehab
Clinical scale
375+ rehabilitation centers worldwide; 200+ published articles; 2,000+ patients across 185+ clinical studies
Americas revenue Q1 2026
$1.55M (US $1.53M)
Going concern
Q1 2026 10-Q discloses substantial doubt; cash funds operations into early Q3 2026; Business Combination with Applied Digital Cloud pending
Go-to-market partners
National Seating & Mobility, Bionic Prosthetics & Orthotics Group, Ottobock Patient Care

Safety record

No incidents on record for EksoNR at United States.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Trust tier
Catalog entry · 2 sources · not yet field-verifiedhow tiers work →
Last updated
2026-07-22
Model
EksoNR
Company
Ekso Bionics
Location
United States
Operator
Ekso Bionics
Status
operational
Operator type
maker operated
ID
cbb9eca5-f3b7-4400-a536-a8b6c8b973f6

Timeline

  1. Jun 2026
    created
  2. Jul 2026
    Current status: operational, reviewed
    Latest recorded state. New status transitions append here as the deployment-status recorder produces them.

On the deployment map

EksoNR operates in United States. Explore the full verified map:

Sources (2)

  1. https://eksobionics.com/en/eksonr/
  2. https://ir.chronoscale.com/press-releases/detail/729/ekso-bionics-receives-fda-clearance-to-market-its-eksonr
Methodology: Verified · 2 sources (1 primary) · last reviewed 2026-07-22

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-07-22

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: exoskeleton

Sources by quality tier

1
unclassified
Unclassified source
1
primary-company-ir
Company IR disclosure

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for EksoNR at United States.

Common questions

What is the EksoNR deployment at United States?
EksoNR, built by Ekso Bionics, is recorded as a deployment at United States on the DEPLOY registry. Ekso Bionics operates the deployment directly.
Who operates EksoNR at United States?
Ekso Bionics, the manufacturer of EksoNR, operates this deployment directly. This is a maker-deploys-its-own-product arrangement rather than a customer pilot.
Have there been incidents at the EksoNR deployment at United States?
No active incidents affecting this deployment are recorded on the DEPLOY registry. Absence of recorded incidents is not a guarantee no incident occurred; DEPLOY records only sourced incidents and suppresses retracted ones.

Deploy Watch

Track this deployment.

We notify you when status changes against primary-source evidence, contract events surface, or a related incident is filed.